title: Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study.
abstract: BACKGROUND
  A solubilized 5% BPO gel has been developed to enhance the bioavailability, follicular penetration, and efficacy of BPO.
  
  
  METHODS
  Sixty-five patients with moderate facial acne vulgaris were randomly assigned to apply solubilized 5% BPO gel to one facial side and 5% BPO/1% clindamycin to the contralateral side, twice daily for four or 12 weeks.
  
  
  RESULTS
  The solubilized BPO gel resulted in significantly greater reductions in non-inflammatory lesion count than BPO/clindamycin at weeks 1, 2, 3, 4 and 12 and comparable reductions in inflammatory lesion count at all time points. Mean values for patient satisfaction with acne improvement were comparable and mean levels of erythema, dryness, peeling, stinging/burning and itching were consistently less than mild.
  
  
  CONCLUSIONS
  Compared with BPO/clindamycin, the solubilized BPO gel offers significantly greater reductions in non-inflammatory lesion count and comparable reductions in inflammatory lesion count in the absence of an antibiotic.
authors.affiliation: Physicians Skin Care PLLC, Louisville, KY 40217, USA. USA.
authors.forename: Leon
authors.initials: L
authors.lastname: Kircik
authors.forename: Lawrence
authors.initials: L
authors.lastname: Green
authors.forename: Diane
authors.initials: D
authors.lastname: Thiboutot
authors.forename: Emil
authors.initials: E
authors.lastname: Tanghetti
authors.forename: David
authors.initials: D
authors.lastname: Wilson
authors.forename: Sunil
authors.initials: S
authors.lastname: Dhawan
authors.forename: Lisa
authors.initials: L
authors.lastname: Parr
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001682:Biological Availability; D002648:Child; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D016037:Single-Blind Method; D012995:Solubility; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D005782:Gels; D002981:Clindamycin; D001585:Benzoyl Peroxide